Jed Eugene Rose is an American academic professor,[1] inventor[2] and researcher in the field of nicotine and smoking cessation.
[8] Rose et al. published the first study of the pharmacokinetics of a transdermal nicotine patch in humans in 1984[9] and the subsequently filed US Patent 4920989[10] which was upheld in a priority decision in 1993.
[11][12][13][14] Also in the 1980s, Rose developed novel methods for reaerosolizing selected constituents of tobacco smoke in cigarette-sized devices, a forerunner of modern e-cigarettes.
[21] In a series of studies he and colleagues showed that transdermal nicotine administration reduced craving for cigarettes and that it was efficacious for smoking cessation.
Pfizer pharmaceuticals cited [25] this work as helping to inspire the development of the partial nicotinic agonist varenicline,[26] which is currently the most effective pharmacologic smoking cessation treatment available.
Attenuating these cues, while holding nicotine intake constant, significantly reduced the psychological rewarding and satiating effects of cigarette smoke.